AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma

[1] van de Donk N(2021)Multiple myeloma Lancet 397 410-427

[2] Pawlyn C(2021)Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients Blood Adv 5 1097-1101

[3] Yong KL(2017)Multiple myeloma Nat Rev Dis Primers 3 17046-34

[4] Mohyuddin GR(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-30

[5] Rooney A(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-1650

[6] Balmaceda N(2021)CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma Molecular Cancer 20 84-3640

[7] Aziz M(2020)Bufalin: a systematic review of research hotspots and antitumor mechanisms by text mining and bioinformatics Am J Chin Med 48 1633-32

[8] Sborov DW(2019)A research update on the anticancer effects of bufalin and its derivatives Oncol Lett 17 3635-3665

[9] McClune B(2018)BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway Int Immunopharmacol 64 24-217

[10] Kumar SK(2019)New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin Cancer Cell Int 19 92-80

[1] van de Donk N(2021)Multiple myeloma Lancet 397 410-427

[2] Pawlyn C(2021)Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients Blood Adv 5 1097-1101

[3] Yong KL(2017)Multiple myeloma Nat Rev Dis Primers 3 17046-34

[4] Mohyuddin GR(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-30

[5] Rooney A(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-1650

[6] Balmaceda N(2021)CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma Molecular Cancer 20 84-3640

[7] Aziz M(2020)Bufalin: a systematic review of research hotspots and antitumor mechanisms by text mining and bioinformatics Am J Chin Med 48 1633-32

[8] Sborov DW(2019)A research update on the anticancer effects of bufalin and its derivatives Oncol Lett 17 3635-3665

[9] McClune B(2018)BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway Int Immunopharmacol 64 24-217

[10] Kumar SK(2019)New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin Cancer Cell Int 19 92-80